Delgocitinib
Jump to navigation
Jump to search
Clinical data | |
---|---|
Trade names | Corectim |
Other names | JTE-052; JTE-052A |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
Chemical and physical data | |
Formula | C16H18N6O |
Molar mass | 310.361 g·mol−1 |
3D model (JSmol) | |
| |
|
Delgocitinib (brand name Corectim) is a pharmaceutical drug for the treatment of autoimmune disorders and hypersensitivity, including inflammatory skin conditions.[1] Delgocitinib was developed by Japan Tobacco and approved in Japan for the treatment of atopic dermatitis.[1] In the United States, delgocitinib is in Phase III clinical trials and the Food and Drug Administration has granted delgocitinib Fast Track designation for topical treatment of adults with moderate to severe chronic hand eczema.[2]
Delgocitinib works by blocking activation of the JAK-STAT signaling pathway which contributes to the pathogenesis of chronic inflammatory skin diseases.[3]
References
- ^ a b Dhillon S (April 2020). "Delgocitinib: First Approval". Drugs. 80 (6): 609–615. doi:10.1007/s40265-020-01291-2. PMID 32166597. S2CID 212681247.
- ^ Park B (August 5, 2020). "Delgocitinib Cream Gets Fast Track Status for Chronic Hand Eczema". empr.com.
- ^ Szalus K, Trzeciak M, Nowicki RJ (November 2020). "JAK-STAT Inhibitors in Atopic Dermatitis from Pathogenesis to Clinical Trials Results". Microorganisms. 8 (11): 1743. doi:10.3390/microorganisms8111743. PMC 7694787. PMID 33172122.
Categories:
- Articles with short description
- Short description matches Wikidata
- Drugs with non-standard legal status
- Articles without EBI source
- Articles containing unverified chemical infoboxes
- Dermatologic drugs
- Non-receptor tyrosine kinase inhibitors
- Pyrrolopyrimidines
- Spiro compounds
- Nitriles
- Amides
- All stub articles
- Antineoplastic and immunomodulating drug stubs